Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + Everolimus in Relapsed/Refractory Lymphoma
NCT00967044Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2009
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat, everolimus in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2009; status: completed.
02
Drugs
panobinostateverolimus
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00967044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967044.